看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。: `5 @% A! S7 B/ \
4 A- c$ @3 o7 h2 p! q5 y% G2 W. w/ n1 k6 G: y. A3 `0 [
Currently available feasibility data for possible combination strategies.
5 e/ C% ?; _ X————————————————————————————————
( M. K4 V) a8 F" \' D6 }Combination Feasibility according to preliminary data
: \ S4 i6 Y- U! j" t. ~" T* M——————————————————————————————————, e, p9 t6 ~$ {8 O. U7 e
Bevacizumab + sorafenib Yes, reduced dose 4 U3 I( {6 D, b6 I( o, D5 f* T8 C2 H
Bevacizumab + sunitinib† No 9 q0 n0 o' D) }; I0 ~! o% j
Bevacizumab + temsirolimus Yes
* |1 |' K* S, Q, WBevacizumab + everolimus Yes ) y4 w7 n3 }% P* b$ j8 l3 v
Sorafenib + sunitinib ?
& Q, t& U: _; _* n( W" T0 x+ oSorafenib + temsirolimus Yes, reduced dose
# }; _+ g& E3 C% l, m9 t2 wSorafenib + everolimus Yes, reduced dose ; s' J4 A# b8 P* \; d" d! P
Sunitinib + temsirolimus† No % N g3 e9 I" j! A8 _
Sunitinib + everolimus ? : v) B4 V! ]8 N. M7 N. K5 e: e
Temsirolimus + everolimus ?
: o$ B0 j: E4 j% r0 H/ d( l# L0 z* b————————————————————
, G) c1 A. g8 r, p†Led to US FDA warning.+ D+ ~: ?1 Y" r% `
?: As yet unattempted combination.. F5 v$ J% x6 M: v, h& h
|